New TB vaccine in sight
“In my opinion this meeting is one of the most significant events in TB history [because of] the spectacular results presented today [on progress towards a TB vaccine] for the first time in a century,” said Professor Thomas Ottenhoff from the global non-profit The Tuberculosis TB Initiative.
He was speaking at a press briefing on Tuesday in The Netherlands ahead of the 49th Union World Conference on Lung Health where the results for a new TB vaccine were presented.
Developed by Glaxo Smith Kline (GSK) and Aeras the M72 vaccine is the most successful vaccine candidate for TB in a century: there was a 54 percent reduction in TB disease in vaccinated study participants.
This is according to GSK’s Marie-Ange Demoitie who said these results had come after the pharmaceutical company, partnering with non-profit Aeras, had been working on the vaccine for two decades.
BCG vaccine
The only existing TB vaccine, known as BCG, was developed a century ago and prevents serious forms of TB in children but has not worked to protect adults.
“Modelling [studies] have already shown that a 50 percent effective vaccine, which this is, could save millions of lives and avert tens of millions of cases of TB,” said Dr Ann Ginsberg from the International Aids Vaccine Initiative.
Since 2014 researchers have studied the protective effect of M72 in 3500 people in three African countries: South Africa, Kenya and Zambia.
The results now have to be confirmed in a bigger study before it can be rolled out in counties.
According to the Union Against Tuberculosis and Lung Disease’s scientific director Dr Paula Fujiwara, an effective vaccine is essential to meet the United Nations’ target of ending TB by 2030.
“[To end TB] we need much more of the promising news we are hearing today and TB research and development needs to be drastically stepped up,” she said. – Health-e News
An edited version of this story was published on Health24.com
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
New TB vaccine in sight
by Amy Green, Health-e News
October 24, 2018